Previous 10 | Next 10 |
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Cellectis S.A. (CLLS) is expected to report $-0.36 for Q3 2023
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financi...
2023-11-01 15:05:07 ET A Paris-based %Healthcare company saw an insanely bullish session on Wednesday after it was announced that %AstraZeneca (Nasdaq: $AZN) said it will acquire a stake in the company and enter into research collaboration, according to a press release. Shares o...
2023-11-01 14:11:42 ET Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures. And in this vast landscape, one metric stands out: volume. It’s like the heartbeat of a stock, echoing its vitality and momentum. Today, we...
2023-11-01 12:08:13 ET DENVER, Colo., Nov. 1, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Aldeyra Therapeutics Inc (NASDAQ: ALDX), Cellectis SA (NASDAQ: CLLS), TG Therapeutics, Inc. (NASDAQ: TG...
2023-11-01 09:58:41 ET DENVER, Colo., Nov. 1, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Cellectis SA (NASDAQ: CLLS), TG Therapeutics, Inc. (NASDAQ: TGTX), Monopar Therapeutics Inc. (NASDAQ: MNPR), A...
Collaboration leverages Cellectis’ gene editing technologies and manufacturing capabilities to develop up to 10 novel cell & gene therapy candidate products Cellectis to receive up to $245M in cash (up to $220M equity investment and $25M upfront payment), with potential...
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical da...
NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that they will be sh...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...